XRX.CN
XORTX Therapeutics Inc. News
Sign up for free!
Get instant access to all of our market news and analysis with our free REST API.
Latest news
Live response for past 24 hours
{
"meta": {
"found": 2,
"returned": 2,
"limit": 10,
"page": 1
},
"data": [
{
"uuid": "ee1cb629-a04a-49c3-95a7-d62f7af8e6d5",
"title": "XORTX adjusts warrant terms and exercise price By Investing.com",
"description": "XORTX adjusts warrant terms and exercise price",
"keywords": "",
"snippet": "CALGARY, Alberta - XORTX Therapeutics Inc. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company specializing in the treatment of progressive k...",
"url": "https://www.investing.com/news/company-news/xortx-adjusts-warrant-terms-and-exercise-price-93CH-3407540",
"image_url": "https://i-invdn-com.investing.com/news/news_pile_69x52._800x533_L_1419494209.jpg",
"language": "en",
"published_at": "2024-04-30T18:04:29.000000Z",
"source": "investing.com",
"relevance_score": null,
"entities": [
{
"symbol": "XRX.CN",
"name": "XORTX Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 51.267475,
"sentiment_score": 0.76635,
"highlights": [
{
"highlight": "CALGARY, Alberta - <em>XORTX</em> <em>Therapeutics</em> <em>Inc</em>. (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a pharmaceutical company specializing in the treatment of progressive kidney disease, announced today that it has received approval from the TSX Venture Exchange to amend the exercise price of over one million outstanding common share purchase warrants.",
"sentiment": 0.8519,
"highlighted_in": "main_text"
},
{
"highlight": "InvestingPro Insights\n\n<em>XORTX</em> <em>Therapeutics</em> <em>Inc</em>. is navigating challenging financial waters, as reflected in the recent amendment of exercise prices for outstanding warrants. The company's strategic adjustments come at a time when its stock performance and financial metrics raise concerns among investors.",
"sentiment": 0.6808,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
},
{
"uuid": "aa95a2b0-bc10-4ed7-98c3-fd0ddc1a3f43",
"title": "XORTX Reprices Warrants Issued in Connection with Previous Private Placements",
"description": "CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“",
"keywords": "",
"snippet": "This advertisement has not loaded yet, but your article continues below.\n\nXORTX Reprices Warrants Issued in Connection with Previous Private Placements\n\nArticle...",
"url": "https://financialpost.com/globe-newswire/xortx-reprices-warrants-issued-in-connection-with-previous-private-placements-2",
"image_url": "https://dcs-static.gprod.postmedia.digital/16.0.2/websites/images/fp/favicon-fp.ico",
"language": "en",
"published_at": "2024-04-30T17:58:52.000000Z",
"source": "financialpost.com",
"relevance_score": null,
"entities": [
{
"symbol": "XRX.CN",
"name": "XORTX Therapeutics Inc.",
"exchange": null,
"exchange_long": null,
"country": "ca",
"type": "equity",
"industry": "Healthcare",
"match_score": 40.305004,
"sentiment_score": -0.10115,
"highlights": [
{
"highlight": "XORTX Reprices Warrants Issued in Connection with Previous Private Placements\n\nArticle content CALGARY, Alberta, April 30, 2024 (GLOBE NEWSWIRE) — <em>XORTX</em> <em>Therapeutics</em> <em>Inc</em>.",
"sentiment": 0,
"highlighted_in": "main_text"
},
{
"highlight": "About <em>XORTX</em> <em>Therapeutics</em> <em>Inc</em>. XORTX is a pharmaceutical company with two clinically advanced products in development: 1) our lead, XRx-008 program for ADPKD; and 2) our secondary program in XRx-101 for acute kidney and other acute organ injury associated with Respiratory Viral infection.",
"sentiment": -0.2023,
"highlighted_in": "main_text"
}
]
}
],
"similar": []
}
]
}
Sentiment
Live response for past 24 hours
{
"meta": {
"returned": 1,
"limit": 10
},
"data": [
{
"key": "XRX.CN",
"total_documents": 2,
"sentiment_avg": 0.3325999863445759
}
]
}
Other details
Exchange
- Canadian Securities Exchange
- equity
- Healthcare
- ca